AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T20:04:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Tue 13 May 25, 08:05 PMVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Tue 11 Mar 25, 08:05 PMVerrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now
Sun 29 Sep 24, 12:02 PM7 Short-Squeeze Stocks That Could Beat Down the Bears
Mon 15 Jul 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Minority interest | - | - | - | - | - |
| Net income | -27.67800M | -38.90300M | -45.49700M | -27.95000M | -20.64800M |
| Selling general administrative | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 8.31M | 12.00M | - | - | 0.00000M |
| Reconciled depreciation | 0.72M | 0.47M | 0.23M | 0.26M | 0.02M |
| Ebit | -21.29600M | -30.90800M | -40.18100M | -30.33700M | -20.66800M |
| Ebitda | -20.87800M | -30.78500M | -39.66100M | -30.08000M | -20.64800M |
| Depreciation and amortization | 0.42M | 0.12M | 0.52M | 0.26M | 0.02M |
| Non operating income net other | -1.01900M | 0.12M | 0.52M | 1.87M | 1.23M |
| Operating income | -21.29600M | -30.90800M | -40.18100M | -30.08000M | -21.87800M |
| Other operating expenses | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M |
| Interest expense | 2.17M | 4.29M | 3.03M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.48M | 0.12M | 0.52M | 1.88M | 1.23M |
| Net interest income | -1.69600M | -4.17200M | -2.51200M | 1.88M | 1.23M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 3.19M | 3.82M | 2.80M | -0.25700M | 1.23M |
| Total revenue | 9.03M | 12.00M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M |
| Cost of revenue | 0.72M | - | - | - | 0.00000M |
| Total other income expense net | -3.19100M | -4.17200M | -2.51300M | 1.87M | -0.00100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Net income applicable to common shares | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 81.60M | 44.72M | 80.12M | 74.15M | 68.42M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.54M | 4.84M | 3.97M | 2.18M | 2.97M |
| Total liab | 61.83M | 4.69M | 47.52M | 41.17M | 3.41M |
| Total stockholder equity | 19.76M | 40.03M | 32.60M | 32.99M | 65.02M |
| Deferred long term liab | - | - | - | 0.10M | - |
| Other current liab | 13.86M | 2.65M | 3.27M | 3.11M | 2.04M |
| Common stock | 0.00400M | 0.00400M | 0.00300M | 0.00300M | 0.00300M |
| Capital stock | 0.00400M | 0.00400M | 0.00300M | 0.00300M | 0.00300M |
| Retained earnings | -230.44800M | -163.45300M | -138.96600M | -103.88600M | -61.19200M |
| Other liab | - | - | - | 5.85M | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.28M | 0.29M | 1.57M | 1.24M |
| Cash | 69.55M | 34.27M | 15.75M | 10.69M | 9.24M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 17.02M | 3.46M | 46.05M | 39.48M | 3.35M |
| Current deferred revenue | - | - | - | 0.50M | - |
| Net debt | -24.03700M | -32.74700M | 27.66M | 24.63M | -9.05300M |
| Short term debt | 0.70M | 0.30M | 41.94M | 35.51M | 0.13M |
| Short long term debt | - | - | 41.69M | 35.31M | - |
| Short long term debt total | 45.51M | 1.53M | 43.41M | 35.31M | 0.19M |
| Other stockholder equity | 250.21M | 203.48M | 171.60M | 136.87M | 126.18M |
| Property plant equipment | - | 3.89M | 3.89M | 4.94M | 2.20M |
| Total current assets | 77.53M | 39.12M | 74.33M | 65.47M | 64.98M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 40.03M | 32.60M | 32.99M | 65.02M |
| Short term investments | - | 0.00000M | 54.60M | 54.78M | 52.78M |
| Net receivables | 4.42M | 0.49M | - | - | - |
| Long term debt | 42.87M | - | - | 35.31M | - |
| Inventory | 1.02M | -0.48700M | - | - | - |
| Accounts payable | 2.46M | 0.51M | 0.84M | 0.35M | 1.19M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | -0.02900M | 0.00100M | 0.02M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00400M | 0.00300M | 0.00300M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -163.45300M | -138.96600M | -103.88600M | -61.19200M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.45M | 0.28M | 0.29M | 3.75M | 1.24M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4.07M | 5.61M | 5.80M | 8.68M | 3.44M |
| Capital lease obligations | 2.64M | 1.53M | 1.72M | 1.89M | 0.19M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 54.52M | 0.09M | -1.88900M | 27.86M | -79.12000M |
| Change to liabilities | -0.59300M | 0.20M | -0.33800M | 0.01M | 1.86M |
| Total cashflows from investing activities | 54.04M | -0.99800M | -3.58000M | 25.95M | -79.89400M |
| Net borrowings | -43.76700M | 4.97M | 34.46M | 34.46M | 34.46M |
| Total cash from financing activities | -16.87000M | 33.65M | 35.23M | 0.42M | 99.38M |
| Change to operating activities | -0.97500M | -0.53200M | 1.97M | -1.95300M | 0.14M |
| Net income | -24.48700M | -35.08000M | -42.69400M | -28.20700M | -20.64800M |
| Change in cash | 18.52M | 5.07M | 1.45M | -1.03000M | 1.61M |
| Begin period cash flow | 15.75M | 10.69M | 9.24M | 10.27M | 8.66M |
| End period cash flow | 34.27M | 15.75M | 10.69M | 9.24M | 10.27M |
| Total cash from operating activities | -18.65000M | -27.58200M | -30.20700M | -27.40800M | -17.87400M |
| Issuance of capital stock | 26.90M | 28.12M | - | 0.00000M | 107.25M |
| Depreciation | 0.72M | 0.47M | 0.23M | 0.26M | 0.02M |
| Other cashflows from investing activities | -0.18000M | -0.20100M | -0.22100M | -1.22400M | -0.49900M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.48700M | -0.48700M | 0.41M | -0.48700M | - |
| Sale purchase of stock | 26.90M | 28.68M | 0.45M | 0.42M | 78.38M |
| Other cashflows from financing activities | -0.01700M | 5.53M | 35.23M | 0.42M | 13.13M |
| Change to netincome | 6.80M | 7.50M | 10.62M | 3.33M | 2.25M |
| Capital expenditures | 0.30M | 0.88M | 1.47M | 0.68M | 0.77M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | -0.93700M | -0.51200M | 1.71M | -1.54700M | -0.92300M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 18.52M | 5.07M | 1.45M | -1.03000M | 1.61M |
| Change in working capital | -1.80000M | -0.53500M | 1.64M | -1.72800M | 0.94M |
| Stock based compensation | 4.99M | 6.05M | 9.82M | 3.33M | 2.25M |
| Other non cash items | 1.93M | 1.44M | 0.94M | -1.06300M | -0.43500M |
| Free cash flow | -18.95200M | -28.46500M | -31.67700M | -28.09000M | -18.64800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals Inc |
0.28 4.77% | 6.15 | - | - | 56.87 | 14.83 | 52.51 | -4.3262 |
| NVO Novo Nordisk A/S |
1.75 4.17% | 43.75 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.78 4.22% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
13.40 3.13% | 441.74 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
9.78 1.58% | 628.73 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
44 West Gay Street, West Chester, PA, United States, 19380
| Name | Title | Year Born |
|---|---|---|
| Mr. Ted White | Pres, CEO & Director | 1965 |
| Mr. Joe Bonaccorso | Chief Commercial Officer | 1964 |
| Dr. Gary Goldenberg M.D. | Chief Medical Officer | 1977 |
| Mr. P. Terence Kohler | Chief Financial Officer | NA |
| Mr. Christopher G. Hayes | Chief Legal Officer, Sec., Chief Compliance Officer & Gen. Counsel | 1964 |
| Mr. Eugene Scavola | Exec. VP of Technical Operations | NA |
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Devel. | NA |
| Mr. Ted White | President, CEO & Director | 1965 |
| Mr. Christopher G. Hayes | Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel | 1964 |
| Mr. Eugene Scavola | Executive Vice President of Technical Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...